期刊文献+

阿托伐他汀和辛伐他汀对降脂及消退颈动脉斑块疗效的对比研究 被引量:6

Comparison of atorvastatin and simvastatin in hypolipemic effect and atheromatous plaque resolution of carotid artery in senile patients with hyperlipemia
下载PDF
导出
摘要 目的:比较阿托伐他汀和辛伐他汀消退老年人颈动脉粥样斑块及降脂疗效。方法:选择存在颈动脉粥样斑块的143例高脂血症的老年患者,随机分为阿托伐他汀组(n=72)及辛伐他汀组(n=71)。阿托伐他汀组每晚服阿托伐他汀10 m g,辛伐他汀组每晚服辛伐他汀20 m g,均连续服药12周。观察其对血脂各项指标(TC、TG、LDL-C、HDL-C)及肝肾功能的影响,并进行颈动脉多普勒超声检查。结果:两药均能降低TC、TG和升高HVD-C,治疗前后比较差异有显著性(P<0.01);同时两药对老年人颈动脉粥样斑块均有一定的消退作用,但阿托伐他汀优于辛伐他汀。结论:阿托伐他汀能明显降低血脂,能消退颈动脉粥样斑块,且阿托伐他汀的降脂和消退斑块疗效优于辛伐他汀。 Objective: To compare the effects of atorvastatin versus simvastatin on lipid-lowering and atheromatous plaque resolution of carotid artery in senile patients with hyperlipemia. Methods: A total of 143 gerOntal patients with hyperlipemia and carotid atheromatous plaques were randomly divided into atorvastatin group (n=72) and simvastatin group (n=71), and both groups received atorvastatin (10mg/d) and simvastatin (20mg/d) for 12 weeks, respectively. The blood lipid, liver and renal function, and the carotid plaques before and after the treatment were determined by biochemical analyzer and Doppler ultrasonography, respectively. Results: TC and TG levels decreased, and HDL-C contents increased significantly after atorvastatin or simvastatin treatment (P〈0.0l). The atheromatous plaques of carotid artery in both groups showed obvious resolution, especially in atorvastatln group. Conclusion: The lipid-lowering efficacy and carotid plaque resolution of atorvastatin are superior to those of simvastain in elderly patients with hyperlipemia.
出处 《广东医学院学报》 2006年第1期5-7,共3页 Journal of Guangdong Medical College
关键词 阿托伐他汀 辛伐他汀 颈动脉斑块 高脂血症 彩色超声 atorvastatin simvastatin carotid plaques hyperlipemia, eolour ultrasonography
  • 相关文献

参考文献10

  • 1THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP.Randomised trial of cholesterol lowering in 4444 patients with coronary heart diseases:the Scandinvavian Simvastatin Survival Study(4S)[J].Lancet,1994,344(8934):1383-1389.
  • 2程纯,吴士尧.普伐他汀对冠心病患者颈动脉粥样斑块的影响[J].中国临床药学杂志,2001,10(3):140-143. 被引量:25
  • 3LEA A P,McTAVISH D.Atorvastatin,a review of its pharmacology and therapeutic potential in the management of hyperlipidemias[J].Drugs,1997,53(5):828-847.
  • 4SHEPHERD J,COBBE S M,FORD I,et al.Prevent of coronary heart disease with provastatin in men with hypercholesterolemia[J].N Engl J Med,1995,333(20):1301-1307.
  • 5SACKS F M,PFEFFER M A,MOYE L A,et al.The effect of pravestation on coronary events after myocardial infarction in patients with average cholesterol levels[J].N Engl J Med,1996,335(14):1001-1009.
  • 6BLANKENBORN D H,AZEN S P,KRAMSH D M,et al.Coronary angiographic changes with lovastatin therapy,the monitored atherosclerosis regression study (MARS)[J].Ann Intern Med,1993,119(10):969-976.
  • 7OLIVER M F,De FEYTER P J,LUBSEN J,et al.Effects of simavastarin on coronary atheroma:the Multicentre Anti-Aatheroma Study (MAAS)[J].Lancet,1994,344(8924):762.
  • 8王增武,满荣海,史平,武阳丰,陆宗良.他汀类药物预防心血管病事件的非调脂机制[J].心血管病学进展,2003,24(1):1-4. 被引量:63
  • 9许竹梅,赵水平,聂赛,周宏年,李全忠,刘玲.阿托伐他汀增加单核细胞过氧化物酶增殖体激活受体γ表达改善炎症反应[J].中华心血管病杂志,2004,32(4):329-332. 被引量:41
  • 10曾群英,张育君.辛伐他汀治疗冠心病并高胆固醇血症的临床研究[J].新医学,1998,29(S1):13-15. 被引量:6

二级参考文献13

  • 1黄铮,龚兰生,施仲伟,沈卫峰,于金德.冠心病患者颈动脉粥样硬化斑块的好发部位及其超声分型[J].中国超声医学杂志,1996,12(5):34-37. 被引量:194
  • 2Ishibashi M, Egashira K, Hiasa K, et al. Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension, 2002, 40:687-693.
  • 3Pasceri V, Wu HD, Willerson JT, et al. Modulation of vascular inflammation in vivo and in vitro by peroxisome proliferators-activator-γ activators. Circulation, 2000,101:235-238.
  • 4Libby P. Current concepts of the pathogenesis of the acute coronary syndrome. Circulation, 2001, 104: 365-372.
  • 5Jovinge S, Ares MP, Kallin J, et al. Human monocytes/macrophages release TNF-alpha in responsible to OxLDL. Atherioscler Thromb Vasc Biol, 1996, 16: 1573-1579.
  • 6The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994,344:1383-1389.
  • 7Inoue S, Egashira K, Ni W, et al. Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atheroslerosis in apolipoprotein E-Knockout mice. Circulation, 2002, 106: 2700-2706.
  • 8Brown DL, Hibbs MS, Kearney M,et al. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation, 1995, 91:2125-2131.
  • 9Galis ZS, Johnson C, Godin D, et al. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res, 2002, 91:852-859.
  • 10Baker AH, Edwards DR, Murphy G,et al. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci, 2002, 115:3719-3727.

共引文献127

同被引文献77

引证文献6

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部